Skip to main content

ReachMD™ Resources| OLYSIO® | HCP

In this 15-minute audio broadcast, the perspectives of Dr. Eric Lawitz, medical director
at the Texas Liver Institute, will be featured.

Dr. Lawitz, lead investigator for the Janssen COSMOS clinical trial of OLYSIO®
(simeprevir) in combination with sofosbuvir, talks about trends in hepatitis C. He also
focuses on OLYSIO®, discussing its appropriate use and limitations, how physicians can
best determine whether OLYSIO® is right for their patients, including that patients on
OLYSIO® can continue to take their proton pump inhibitors to manage gastroesophageal
reflux with no interaction.